版权说明:本文档由用户提供并上传,收益归属内容提供方,若内容存在侵权,请进行举报或认领
文档简介
HaffnerSM,AlexanderCM,CookTJ,BoccuzziSJ,MuslinerTA,PedersenTR,KjekshusJ,PyoralaKforthe4SGroupReducedCoronaryEventsinSimvastatin-TreatedSubjectswithCHDandDiabetesorImpairedFastingGlucose:SubgroupAnalysesintheScandinavianSimvastatinSurvivalStudy
ArchInternMed1999;159:2661-2667HaffnerSM,AlexanderCM,CookExpanded4SDiabetesAnalysisDiabetesMellitusbyHistory202Subjects(Original4SDiabetesSubgroup)FG>126mg/dl,butNoHistoryofDiabetes281SubjectsImpairedFastingGlucose(FG110-125mg/dl)678SubjectsNormal(FG<110mg/dl)3,237SubjectsHaffnerSM,etal.ArchInternMed1999;159:2661-2667Expanded4SDiabetesAnalysisDRationale&GoalsRationaleNewADADiagnosticCriteriaforDM(FG>126mg/dl)NewCategoryofIFG(FG110-125mg/dl)GoalsConfirmpreviousdataPerformanalysisof4SsubjectswithIFGHaffnerSM,etal.ArchInternMed1999;159:2661-2667Rationale&GoalsRationaleHaffBaselineCharacteristics
Normal IFG DM-FG DM-Hxn 3237 678 281 202Age 59 59 59 60Male(%) 80 84 89 78SBP 138 139 141 147Tot-C 261 261 261 259LDL-C 189 189 186 189HDL-C 46 45 44 44TG 130 137 142 153FG 95 117 136 175HaffnerSM,etal.ArchInternMed1999;159:2661-2667BaselineCharacteristics NormaPercentChangeinLipidsandLipoproteinsin4SHaffnerSM,etal.ArchInternMed1999;159:2661-2667PercentChangeinLipidsandLIncidenceofMajorCHDEventsbyGlucoseStatusinthe4SPlaceboGroupNFG(n=1631)IFG(n=335)DM-FG(n=135)DM-history(n=97)BaselineGlucoseStatusHaffnerSM,etal.ArchInternMed1999;159:2661-2667IncidenceofMajorCHDEvents4S~MajorCoronaryHeartDiseaseEventsRR= 0.68 0.62 0.58pvalue=<0.001 0.003 0.001n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S~MajorCoronaryHeartDise4S&RevascularizationsRR= 0.67 0.57 0.52pvalue=<0.001 0.01 0.005n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S&RevascularizationsRR= 4S~TotalMortalityRR= 0.72 0.57 0.79pvalue=0.005 0.02 0.34n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S~TotalMortalityRR= IFGSubjects(n=678)0.00.20.40.60.81.01.21.4RelativeRiskMCERevascularizationTotMortalityCHDMortalityp=0.003p=0.009p=0.02p=0.0070.620.570.570.45HaffnerSM,etal.ArchInternMed1999;159:2661-2667IFGSubjects(n=678)0.00.20.40DiabeticSubjects(n=483)0.00.20.40.60.81.01.21.4RelativeRiskMCERevascularizationTotMortalityCHDMortalityp=0.001p=0.005p=0.34p=0.260.580.520.790.72HaffnerSM,etal.ArchInternMed1999;159:2661-2667DiabeticSubjects(n=483)0.00.
MajorCHDEventsNFGSimvastatinNFGPlaceboIFGSimvastatinIFGPlaceboDMSimvastatinDMPlaceboArchInternMed1999;159:2661-2667MajorCHDEventsNFGSimvastEffectsofSimvastatinonMajorCoronaryEventsbyGlucoseStatusStratifiedbyLevelofLipidParametersArchInternMed1999;159:2661-2667EffectsofSimvastatinonMajoAbsoluteandRelativeRiskBenefitofSimvastatinTherapybyGlucoseStatusforMajorCoronaryEvents NFG IFG DMSimvastatingroup,No.(%) 299/1606(18.6)67/343(19.5)59/251(23.5)Placebogroup,No.(%) 428/1631(26.2)102/335(30.5)87/232(37.5)Relativerisk 0.68 0.62 0.58Prelativerisk <0.001 0.003 0.001Absolutebenefit(Kaplan-Meieryear6estimate) 8.02/100cases12.11/100cases13.85/100casesNumberneededtotreat 12 8 7HaffnerSM,etal.ArchInternMed1999;159:2661-2667AbsoluteandRelativeRiskBenSummary-DiabetesMellitusHighereventrateindiabetesgroup,byhistory,comparedtoothergroupsIncombinedDMgroup(byhistoryandfastingglucose):MajorCoronaryEventswerereducedby42%(p=0.001)Revascularizationswerereducedby48%(p=0.005)Totalandcoronarymortalitywerereduced,butreductionsnotsignificantduetosmallsamplesizeHaffnerSM,etal.ArchInternMed1999;159:2661-2667Summary-DiabetesMellitusHigSummary-ImpairedFastingGlucoseReducedtotalmortalityby43%(p=0.02)Reducedcoronarymortalityby55%(p=0.007)Reducedmajorcoronaryeventsby38%(p=0.003) Reducedtheneedforrevascularizationproceduresby43%(p=0.009)HaffnerSM,etal.ArchInternMed1999;159:2661-2667Summary-ImpairedFastingGluConclusionsThisanalysisconfirmsandextendsthebenefitofcholesterolloweringwithsimvastatininanexpandedcohortofpatientswithdiabetesandovertCHDCHDpatientswithimpairedfastingglucose
(FG110to125mg/dL)benefitfromtreatmentwithsimvastatinbysignificant&substantialreductionsintotalandcoronarymortality,majorCHDeventsandrevascularizations.HaffnerSM,etal.ArchInternMed1999;159:2661-2667ConclusionsThisanalysisconfiHaffnerSM,AlexanderCM,CookTJ,BoccuzziSJ,MuslinerTA,PedersenTR,KjekshusJ,PyoralaKforthe4SGroupReducedCoronaryEventsinSimvastatin-TreatedSubjectswithCHDandDiabetesorImpairedFastingGlucose:SubgroupAnalysesintheScandinavianSimvastatinSurvivalStudy
ArchInternMed1999;159:2661-2667HaffnerSM,AlexanderCM,CookExpanded4SDiabetesAnalysisDiabetesMellitusbyHistory202Subjects(Original4SDiabetesSubgroup)FG>126mg/dl,butNoHistoryofDiabetes281SubjectsImpairedFastingGlucose(FG110-125mg/dl)678SubjectsNormal(FG<110mg/dl)3,237SubjectsHaffnerSM,etal.ArchInternMed1999;159:2661-2667Expanded4SDiabetesAnalysisDRationale&GoalsRationaleNewADADiagnosticCriteriaforDM(FG>126mg/dl)NewCategoryofIFG(FG110-125mg/dl)GoalsConfirmpreviousdataPerformanalysisof4SsubjectswithIFGHaffnerSM,etal.ArchInternMed1999;159:2661-2667Rationale&GoalsRationaleHaffBaselineCharacteristics
Normal IFG DM-FG DM-Hxn 3237 678 281 202Age 59 59 59 60Male(%) 80 84 89 78SBP 138 139 141 147Tot-C 261 261 261 259LDL-C 189 189 186 189HDL-C 46 45 44 44TG 130 137 142 153FG 95 117 136 175HaffnerSM,etal.ArchInternMed1999;159:2661-2667BaselineCharacteristics NormaPercentChangeinLipidsandLipoproteinsin4SHaffnerSM,etal.ArchInternMed1999;159:2661-2667PercentChangeinLipidsandLIncidenceofMajorCHDEventsbyGlucoseStatusinthe4SPlaceboGroupNFG(n=1631)IFG(n=335)DM-FG(n=135)DM-history(n=97)BaselineGlucoseStatusHaffnerSM,etal.ArchInternMed1999;159:2661-2667IncidenceofMajorCHDEvents4S~MajorCoronaryHeartDiseaseEventsRR= 0.68 0.62 0.58pvalue=<0.001 0.003 0.001n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S~MajorCoronaryHeartDise4S&RevascularizationsRR= 0.67 0.57 0.52pvalue=<0.001 0.01 0.005n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S&RevascularizationsRR= 4S~TotalMortalityRR= 0.72 0.57 0.79pvalue=0.005 0.02 0.34n= 1631/1606 335/343232/251HaffnerSM,etal.ArchInternMed1999;159:2661-26674S~TotalMortalityRR= IFGSubjects(n=678)0.00.20.40.60.81.01.21.4RelativeRiskMCERevascularizationTotMortalityCHDMortalityp=0.003p=0.009p=0.02p=0.0070.620.570.570.45HaffnerSM,etal.ArchInternMed1999;159:2661-2667IFGSubjects(n=678)0.00.20.40DiabeticSubjects(n=483)0.00.20.40.60.81.01.21.4RelativeRiskMCERevascularizationTotMortalityCHDMortalityp=0.001p=0.005p=0.34p=0.260.580.520.790.72HaffnerSM,etal.ArchInternMed1999;159:2661-2667DiabeticSubjects(n=483)0.00.
MajorCHDEventsNFGSimvastatinNFGPlaceboIFGSimvastatinIFGPlaceboDMSimvastatinDMPlaceboArchInternMed1999;159:2661-2667MajorCHDEventsNFGSimvastEffectsofSimvastatinonMajorCoronaryEventsbyGlucoseStatusStratifiedbyLevelofLipidParametersArchInternMed1999;159:2661-2667EffectsofSimvastatinonMajoAbsoluteandRelativeRiskBenefitofSimvastatinTherapybyGlucoseStatusforMajorCoronaryEvents NFG IFG DMSimvastatingroup,No.(%) 299/1606(18.6)67/343(19.5)59/251(23.5)Placebogroup,No.(%) 428/1631(26.2)102/335(30.5)87/232(37.5)Relativerisk 0.68 0.62 0.58Prelativerisk <0.001 0.003 0.001Absolutebenefit(Kaplan-Meieryear6estimate) 8.02/100cases12.11/100cases13.85/100casesNumberneededtotreat 12 8 7HaffnerSM,etal.ArchInternMed1999;159:2661-2667AbsoluteandRelativeRiskBenSummary-DiabetesMellitusHighereventrateindiabetesgroup,byhistory,comparedtoothergroupsIncombinedDMgroup(byhistoryandfastingglucose):MajorCoronaryEventswe
温馨提示
- 1. 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。图纸软件为CAD,CAXA,PROE,UG,SolidWorks等.压缩文件请下载最新的WinRAR软件解压。
- 2. 本站的文档不包含任何第三方提供的附件图纸等,如果需要附件,请联系上传者。文件的所有权益归上传用户所有。
- 3. 本站RAR压缩包中若带图纸,网页内容里面会有图纸预览,若没有图纸预览就没有图纸。
- 4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
- 5. 人人文库网仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对用户上传分享的文档内容本身不做任何修改或编辑,并不能对任何下载内容负责。
- 6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
- 7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。
最新文档
- 第二单元探索1 物联网的传感技术 教学设计 2024-2025学年 苏科版(2023)初中信息科技 八年级上册
- 第一单元 活动1 认识Scratch和小猫喵喵 教案( )
- 地理:《高考22类地理常见简答题标准答题思路》教案地理
- 初中地理人教版七下《澳大利亚》第一课时 教学设计
- 2022年6月天津市普通高中学业水平合格性考试化学试卷
- 3.1水循环(课件)高一地理同步高效课堂(人教版2019必修一)
- 房地产市场报告-2024年9月全国租赁市场月报
- 2024电梯制造与安装安全规范
- 200挖机包月合同协议书范文
- 《种树郭橐驼传》课件+2023-2024学年统编版高中语文选择性必修下册
- 采购合同(月饼)
- 防焊掉桥原因分析与改善
- 国家学生体质健康标准数据管理与分析系统培训(学校用户)
- 药企实验室电子数据与审计追踪审核管理规程
- 四年级英语阅读理解训练
- 燃气轮机千瓦价格排序
- 五必访,五必谈——员工思想出现波动谈话
- 农村生活污水治理工程施工设计方案
- 小学一年级数学试题常用字(共4页)
- BS4449-2005混凝土配筋用钢(中文版)
- 水污染控制工程试题库精选
评论
0/150
提交评论